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2007-2011, with a 2-year history and a 3-year follow-up censored at the end of 2012, 
was designed in the EGB, a 1/97 random sample of the French national healthcare 
claims and hospitalization database. AF population was defined as patients with full 
coverage for AF, hospitalization or probabilistic AF information in the database, and 
without other probable cause of VKA prescription. NVAF population was defined as 
patients of the AF population without valvular disease history. Outcomes were the 
first hospitalization for bleeding, arterial thrombotic event (ATE), acute coronary 
syndrome (ACS), and death. Incidence rate of outcomes was estimated during VKA 
exposure. Results: Among 8,894 patients identified, 3,345 were classified in the 
AF population (3,977 person-years (PY)). Half were male (52%) with a mean age of 75 
years, 87% had a CHA2DS2-VASc score ≥ 2, and 12% a HAS-BLED score > 3. The inci-
dence rate of bleeding was 28 patients (95%CI [23-34]) for 1,000 PY exposed to VKA, 
including 6 [3-8] cerebral, 10 [7-13] digestive, and 14 [10-17] other bleeds. Incidence 
rates were 16 [12-20] for ACS, 15 [11-18] for ATE, and 38 [32-44] deaths for 1 000 PY 
exposed to VKA. Patient characteristics and incidence rates were very close for the 
2 818 patients with NVAF population criteria (3,367 PY). For this last population, 
incidence rates were 28 [22-34] for bleeding, 16 [12-20] for ACS, 15 [11-19] for ATE, and 
35 [29-41] deaths for 1 000 PY exposed to VKA. ConClusions: This study provides 
background reference for bleeding, ischemic events, and deaths before introduc-
tion of DOAC for NVAF with quite same frequency for AF and NVAF populations.
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objeCtives: Genetic factors have a great impact on the therapeutic dose of warfarin, 
a commonly prescribed anticoagulant. We still don’t consider them when prescrib-
ing warfarin, despite the high incidence of major and minor gastrointestinal (GI) 
bleeds. We evaluated the potential differential impact of warfarin-related GI bleeds 
risk factors according to the partient’s genetic profile. Methods: This study is based 
on a prospective cohort of new warfarin-users whose objectives were to assess the 
genetic, clinical and environmental risks associated with the effectiveness and safety 
of warfarin. Data was collected on 1069 patients who began the treatment between 
May 2010 and July 2013. Patients were followed-up each three months up to a year. 
The outcomes were minor and major GI bleeds. We used a multivariate Cox regres-
sion analysis. Results: Mean age was 70.8, 61.8% of patients were men, 68.4% had 
a history of hypertension and 60.8% of dyslipidemia and 76.4% had atrial fibrillation 
as a primary indication for warfarin. Overall, 4.8% of patients reported ≥ 1 minor GI 
bleed and 1.6% reported ≥ 1 major GI bleed. Patients with ≥ 1 polymorphism on both 
the CYP2C9 and the VKORC1 were significantly more at risk of having a major GI bleed 
(HR 10.72; p= 0.023). Patients with a history of MI or angina were at risk of having both 
minor and major GI bleeds (HR= 1.73 and HR= 2.63; p< 0.05). The impact of MI and 
angina disappeared for patients with no SNP on the CYP2C9 gene but was higher for 
patients with ≥ 1 SNP (HR= 2.44 and HR= 5.26, p< 0.05). ConClusions: Our results 
suggest an interaction between MI or angina history and the occurrence of major 
and minor GI bleeds, especially in patients with ≥ 1 polymorphism on the CYP2C9 
gene. Further analysis including concomitant drug use would help clarify clinical 
guidelines for this population and underlie the potential benefit of genetic testings.
PCV47
hosPItal readmIssIons and mortalIty Patterns In a Cohort 
wIth heart faIlure: 1 year follow-uP from the BrazIlIan PuBlIC 
healthCare system dataBase
Asano EW1, Teich V1, Amaral LM2, Fernandes RA2, Fahham L1
1Sense Company, São Paulo, Brazil, 2Sense Company, Rio de Janeiro, Brazil
objeCtives: Heart failure (HF) affects 1.6 million people in Brazil. About 30%-40% 
progress to death in a year. This study aims to report 1-year retrospective analyses of 
hospital readmissions and mortality patterns associated to HF or all-other causes (OC) 
in a Brazilian cohort of patients with HF. Methods: Brazilian Hospital Information 
System (SIH/SUS) database was used to collect hospital readmissions and mortality 
data associated to HF or OC, according to ICD-10 codes (I50.0 and I50.9, and “others”, 
respectively). Patients were followed during 1 year (January-December 2014, regard-
less the entry data). Eligible criteria included patients with one previous HF hospital 
admission. Results: A cohort of 21,015 patients was considered eligible. No HF or OC 
hospital readmissions were observed for 13,050 (62%) and 5,241 (25%) patients, respec-
tively. For HF, 1, 2, 3, 4, and 5 re-hospitalizations were observed for 6,053, 1,255, 395, 152, 
and 59 patients. One patient required ten re-hospitalizations and the same occurred 
for 12 and 15 hospital readmissions. Therefore, about 38%, 9%, 3% and 1% of all 
patients had 1, 2, 3 or 4 hospital readmissions at least. OC readmissions showed higher 
number of patients for each amount of hospitalizations (11,046, 2,965, 989, 415, and 
184 for 1, 2, 3, 4, and 5, respectively). Seven patients required ten re-hospitalizations 
and 1 required 19. Compared to HF, OC showed approximately twice of all patients 
with 1 hospital readmission at least (75%). Mortality rate was 19.23%, 702 (3.34%) due 
to HF and 2,632 (12.52%) due to OC. ConClusions: The number of patients requiring 
hospitals readmissions for HF remain significant, despite available treatment options 
in Brazilian Public Healthcare System. OC results showed higher numbers, however, 
for this analysis all-other hospitalizations causes were included (except HF) indicat-
ing a high presence of comorbidities among this population and/or a misregistration 
at hospitalization time.
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inadequate control of LDL-C levels, despite being adherent to treatment Methods: 
An observational retrospective cohort analysis based on five Local Health Units 
administrative databases was conducted, for a total number of 1.2 Million benefi-
ciaries involved. Patients with at least one LDL-C measurement between January 
1, 2011 and December 31, 2012 were included. Patients were characterized back 12 
months to assess appropriateness and adherence to statin treatment Results: 
Among patients with LDL-C determination (1’218 patients), 578 (47%) and 640 (53%) 
displayed LDL-C under control and out of control, respectively. Among patients with 
uncontrolled LDL-C, 74 (12%) and 566 (88%) were not treated and treated with statins, 
respectively. Among patients with statins treatment, 188 (33%) and 378 (67%) were 
treated with low and high efficacy statins, respectively. Finally, among patients 
treated with high efficacy statins, 225 (60%) and 153 (40%) were non-adherent and 
adherent to high efficacy statin treatment, respectively. LDL-C uncontrolled high 
efficacy adherent patients showed different distances from their lipid target: 28% 
were less than 10% distant, 28.4% were 10-19% distant, 10.5% were 20-29% distant, 
11.1% were 30-39% distant and 24.8% were more than 40% distant ConClusions: 
These results are topical, as new monoclonal antibodies - PCSK9 inhibitors - are 
being marketed to address the residual unmet need in cholesterol statin-manage-
ment of dyslipidaemia for uncontrolled patients. By projecting study percentages to 
the Italian population, the number of LDL-C patients who are uncontrolled, despite 
being adherent to a high efficacy statin, would be around 17’825
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objeCtives: To identify the characteristics and assess the treatment of patients 
diagnosed with ischemic stroke. It was also performed to compare the manage-
ment of ischaemic stroke between current practice with the recommended guide-
line. Methods: Retrospective reviews of the medical records of patients who were 
diagnosed with ischemic stroke at the medical record’s office in a teaching hospital 
from January 1, 2013 to December 31, 2013. Patients’ medication for the treatment of 
stroke at discharge were reviewed and identified. Results: A total of 198 patients 
were diagnosed with ischemic stroke. This was found to be higher in men 104 (52.5%). 
In this study of 198 patients, 108 (54.5%) patients were diagnosed with newly onset 
of stroke and 28 (14.1%) patients were diagnosed with recurrent stroke. The major 
co-morbidities identified were the combination of hypertension and diabetis mel-
litus and hypertension alone, which were seen in 45 (22.7%) patients and 39 (19.7%) 
patients respectively. Aspirin and statin were the most commonly prescribed agent, 
which were 170 (85.9%) and 182 (91.9%) respectively. ConClusions: Majority of our 
patients are male, Malay and in the age range of 50-59. These patients had underly-
ing hypertension and diabetes upon their diagnosis of ischemic stroke. Aspirin and 
statin were mostly prescribed and widely used to treat ischaemic stroke. The current 
guidelines appear to have some influence on the current practice of the management 
of ischemic stroke.
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objeCtives: Elevated serum cholesterol levels are a well-known cause of car-
diovascular events. The objectives of this study were: to review the epidemiology 
of hypercholesterolemia in Spain; to detail the proportion of diagnosed patients 
undergoing pharmacological treatment (PhT); the degree of attained lipid con-
trol, and associated medical costs. Methods: A systematic literature review was 
carried out using Medline (pubmed) and Spanish databases as Medes and Biblioteca 
Virtual de la Salud. Manuscripts containing information on heterozygous familial hyper-
cholesterolemia (HeFH); hypercholesterolemia in primary prevention (PP) (diabetes mel-
litus or SCORE risk > 5) or secondary prevention (SP), published between January 2010 
and October 2014, were included. Results: Of the 1,947 published references initially 
retrieved, a full text review was done on 264 manuscripts and 120 were finally included. 
Prevalence of hypercholesterolemia ranged from 50%-84% in diabetics, 30%-60% in 
patients with high cardiovascular risk, 64%-74% with chronic coronary heart disease, 
33%-97% in acute coronary syndromes, 40%-70% in stroke patients, and 60%-80% in 
those with peripheral artery disease. Despite the finding that 30%-90% of patients were 
on pharmacological treatment, lipid control was found only in 15%-65% of cases in pri-
mary prevention and in 15%-56% of patients in secondary prevention. Among those with 
HeFH 95%-100% were treated but less than 16% achieved LDL-c target. ConClusions: 
An elevated prevalence of hypercholesterolemia can be seen in targeted groups at higher 
cardiovascular risk. Although most patients are receiving pharmacological treatment, 
rates of control continue to be low, both in primary and secondary prevention.
PCV44
BenefIt-rIsk of Vka for atrIal fIBrIllatIon Before doaC: a Cohort 
study In a ClaIms and hosPItalIzatIon dataBase
Blin P1, Dureau-Pournin C1, Lassalle R1, Abouelfath A1, Droz-Perroteau C1, Moore N2
1INSERM CIC1401, ADERA, Bordeaux University, Bordeaux, France, 2INSERM CIC1401, Bordeaux 
University, Bordeaux, France
objeCtives: To assess real-life outcomes in new Vitamin K antagonists (VKA) users 
for atrial fibrillation (AF), before introduction of direct oral anticoagulants (DOAC) 
for non-valvular AF (NVAF). Methods: Cohort study of new VKA users between 
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ones or DPP-4 was associated with reduced risks for cardiovascular events (hazard 
ratio, 0.69; 95% CI, 0.57 to 0.84; P< 0.001 and hazard ratio, 0.71; 95% CI, 0.60 to 0.84; 
P< 0.001, respectively). ConClusions: Among patients with type 2 diabetes who 
were initiating oral diabetes drugs, metformin use was significantly associated with 
a decreased risk of major adverse cardiovascular events. And, the addition of thiazo-
lidinediones or DPP-4 inhibitors vs sulfonyurea on metformin was associated with 
a decreased cardiovascular risk.
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objeCtives: As the effects of statin use on type 2 diabetes mellitus (T2D) are not 
clearly determined, this study evaluated the risk of T2D as well as the benefit of 
cardiovascular disease in the relationship with statin use. Methods: We identi-
fied 5,441071 patients who were eligible for statin therapy and aged 40 years and 
older among National Health Insurance Examinees between January 1, 2005, and 
December 31, 2012. We evaluated the clinical impact of statin use on primary and 
secondary outcome. In addition, we compared the effect of duration or intensity of 
statin use. The primary outcome was new-onset T2D and the secondary outcomes 
included a composite of cardiovascular death, myocardial infarction or stroke, and 
all-cause death. Outcome data were linked with the national claims data of hospital 
admissions and national vital statistics through December 31, 2014. Propensity-
score matching was used to assemble a cohort of patients with similar baseline 
characteristics. Results: A total of 332,449 patients met the inclusion criteria, of 
whom 23,970 (7.21%) used statin therapy. Among them, 23082 pairs was matched 
by propensity-score method, with the consideration of baseline demographic, 
clinical characteristics, comorbidities, and concomitant cardiovascular medication 
factors. ConClusions: The final results of the primary and secondary study out-
comes will be available at ISPOR 18th Annual Euroepan Congress. This large-scale, 
population-based observational study lined with national claim data will provides 
a critical appraisal of effectiveness on new-onset of type 2 diabetes mellitus as well 
as cardiovascular events of statin use.
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objeCtives: Hypertriglyceredemia (HTG) is reported to be associated with acute 
pancreatitis (AP) as an etiological factor and an epiphenomenon. However, evidence 
to establish underlying correlation between TG levels and AP severity is not well 
established. This review was designed to analyse the correlation between acute pan-
creatitis (AP) and increased triglyceride (TG) levels thus defining the etiological role 
of elevated TG levels in AP patients. Methods: A comprehensive search strategy 
was developed and a systematic literature search in Pubmed and EMBASE from 1996 
to June 1, 2015 was carried out to identify studies mentioning triglycerides (TG) and 
acute pancreatitis (AP). Studies were screened using pre-defined inclusion criteria 
after which data from included trials were extracted, by two independent review-
ers and disagreements resolved by a third reviewer. The data was extracted into a 
data extraction form by one reviewer and a thorough quality check was performed 
by the other independent reviewer. Results: Of the 3,797 identified abstracts, 54 
unique studies were included in this review. The majority of the studies reported 
hypertriglyceridemia as an etiology of AP. Only four studies indicated a quantitative 
correlation between elevated TG levels and risk of AP. Amongst these studies, higher 
risk of AP among patients with moderate (150 to 499 mg/dL) and severe HTG (≥ 500 
mg/dL) was reported. Burden of disease (hospital length of stay and mortality) was 
significantly higher in the HTG-induced AP patients than other etiological forms of 
AP. ConClusions: There is paucity of a concrete body of evidence quantifying the 
role of TG levels and risk of AP. Randomized, placebo-controlled trials to determine 
role of TG in AP are highly desirable to substantiate the evidence gaps.
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objeCtives: Healthcare policy for reducing cardiovascular (CV) event burden 
should be guided by current and generalisable data. The objective of the study was 
to estimate 1-year CV event rates in a high-risk general population cohort in the 
UK. Methods: The UK THIN Database was utilised, with inclusion criteria of age 
≥ 18 years and evidence of a high-risk condition for CV events (prior CV disease 
[CVD], diabetes, or chronic kidney disease [CKD]) as of Jan 1, 2010 (index; initiation 
of follow-up). Both treated and untreated patients were included. Patient subgroups 
within CVD were: acute coronary syndrome (ACS) ≤ 12 months pre-index; ACS 12-24 
months pre-index; history of ischaemic stroke; other coronary heart disease (CHD); 
and peripheral arterial disease (PAD). These subgroups were not mutually exclusive 
due to the potential of multiple CVD conditions. Other subgroups included diabetes 
without CVD, and CKD without CVD. One-year risk for the composite endpoint of 
ACS (myocardial infarction or unstable angina), coronary revascularisation, ischae-
mic stroke, and CV death (estimated as 62% of all-cause death based on published 
sources) was estimated via Kaplan-Meier (KM) analyses. Results: A total of 339,943 
individuals met inclusion criteria. Estimated 1-year event rates (%, based on KM 
analysis) for the composite endpoint were: ACS ≤ 12 months, 12.9 (95% CI 11.3-
objeCtives: Heart Fatilure (HF) has become a public health problem reaching epi-
demic levels especially for the elderly population. The objetive of this study was the 
description of patients with HF been treated (followed) in a primary care (PC) area 
in Madrid by the use of data extracted from electronic medical records. Methods: 
A retrospective study was carried out to follow a cohort of 224,320 patients (18yo or 
older visiting PC at least once in 2006) from 01/01/2006 to 12/31/2010. Study outcomes: 
HF prevalent and incident cases, mortality of HF, time diagnosis to dead, GP, Nurse, 
cardiologist visit, hospitalizations and treatment (grouped by ATC-code). Results: 
HF prevalence during the period of study was 2.09% (4,680 patients), 63% women. Of 
these prevalent patients, 1,356 were diagnosed before 2006. The mean age of diagnose 
was 77.28 years (SD 11.52), 74.96 years for males (SD 11.53) and 78.65 (SD 11.29) for 
females. Incident cases during the study period was 3,324 (631 in 2006, 652 in 2007, 
677 in 2008, 703 in 2009 and 661 in 2010). 1,106 had at least one admisión to hospi-
tal. Average number of admisions 1.618 (SD 1.086). And 1028 patients died (22.61%). 
Average time from diagnosis to dead was 1,162 days (SD 1,064). The average yearly 
rate of visits per patient was 14.17 (SD 8.03) for GPs and 10.22 (SD 9.03) for Nurses, 
for consultant cardiologist was 0.10 (SD 0.16). The patients treatment mainly include 
Diuretics (72.93% of patients), Antithrombotic agents (70.96%), Agents acting on the 
renin-angiotensin system (69.89%), Calcium channel blockers (49.12%), Drugs used in 
diabetes (44.89%), Lipid modifying agents (44.17%), Cardiac therapy (38.29%) and Beta 
Blocking agents (37.63%). ConClusions: Despite the improvement of pharmacologi-
cal treatments and the better control of the cardiovascular risk factors. HF continues 
to be responsible for high mortality and a high resource consumption.
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objeCtives: To describe the characteristics and treatment of patients having a 
myocardial infarction (MI) and estimate the incidence of cardiovascular events 
following the index MI, in the French Health Insurance database. Methods: A 
cohort of patients who had an MI in France between 2007 and 2011 was extracted 
from a claims database: the Echantillon Généraliste de Bénéficiaires (a 1% repre-
sentative sample of subjects covered by the general health insurance (≈600,000 
patients). The incidence of cardiovascular events following the index MI was esti-
mated using the Kaplan Meier method. A cox survival model aims to identify fac-
tors related to the composite outcome (death/MI/stroke). Results: 1,920 subjects 
were identified with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had 
diabetes, 37.6% hypercholesterolemia and 82.4% hypertension. Compared to the 
6 months preceding the index MI, rates of use of medications increased in the 
6 months following MI for statins (91.1%/30.7%), Aspirin+other antiplatelet agent 
(82.1%/7.1%), class III antiarrhythmics (8.4%/2.4%), oral anticoagulants (10.1%/5.1%), 
non thiazide diuretics (32.9%/19.1%), ACE-inhibitors (71%/18.6%), beta-blockers 
(86.0%/26.5%), and nitrates (46.4%/9.9%). Cumulative incidences at 1, 2 and 3 years 
after the index MI were: For deaths (all cause and including in-hospital death): 
17.8% (CI95%= 16.0%;19.5%), 21.6% (CI95%= 20.7%;23.5%), 27.0% (CI95%= 25.8%;29.1%); 
For MI (recurrence): 3.1% (CI95%= 2.3%;3.8%), 4.1% (CI95%= 3.2%;5.0%%), 4.7% 
(CI95%= 3.7%;5.7%); For stroke (or transit ischemic attack): 1.9% (CI95%= 1.3%;2.5%), 
3.1% (CI95%= 2.3%;3.9%%), 4.1% (CI95%= 3.1%;5.0%); For the composite outcome 
(death/MI/stroke) : 20.7% (CI95%= 18.9%;22.5%), 26.0% (CI95%= 24.0%;28.0%), 32.1% 
(CI95%= 29.8%;34.3%). A cox multivariate survival model identified the follow-
ing independent correlates of the composite outcome: age (ref < 60y) (60-70y: 
HR= 2.071 CI= [1.051;2.820], 70-80y: HR= 3.463 CI= [2.640;4.541], > 80y: HR= 7.124 
CI= [5.946;9.235]), diabetes (HR= 1.229,CI= [1.028;1.469]) percutaneous coronary inter-
vention (HR= 0.579,CI= [0.457;0.689]), and coronary artery bypass grafting (HR= 0.5
58,CI= [0.359;0.869] ConClusions: Despite high rates of prescription of medical 
therapy, all-cause mortality and CV event rates remained high following MI. This 
underscores the need to improve secondary prevention.
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objeCtives: The cardiovascular outcomes of oral antidiabetic drugs in type 2 diabe-
tes are still unknown. Methods: We identified 1,035,824 patients with type 2 who 
initiated oral antidiabetic drugs in Korea between January 1, 2005, and December 
31, 2011, using national claim data, and outcome data were linked with the national 
registries of hospital admissions and vital statistics. Our study evaluated the cardio-
vascular effects of metformin as initial pharmacotherapy and different second-line 
agents added on metformin. The primary outcome was a composite of cardiovas-
cular death, myocardial infarction, or ischemic stroke, and the follow-up was per-
formed through December 31, 2013 Results: Among 423,081 patients who are 
initiating oral antidiabetic drugs, 208,990 (49.4%) began diabetes treatment with 
metformin. During 3 years of follow-up, the adjusted risk of primary outcomes 
was significantly lower in the metformin user than in the metformin non-user 
(hazard ratio, 0.94; 95% CI, 0.91 to 0.97; P < 0.001). Among 157,509 patients who were 
requiring second-line agents add-on metformin, 123,830 (78.6%) used sulfonylureas, 
9,848 (6.3%) used thiazolidinediones, and 23,831 (15.1%) used dipeptidyl peptidase 
4 [DPP-4] inhibitors. Compared with sulfonyurea, the addition of thiazolidinedi-
